Boehringer Ingelheim

Private pharma

Privately held: no public share price · Germany

Assets

(39 total)
39Total Assets
17Approved
9Phase 3 / Filed
13Phase 1–2 / Early
27Diseases
Quick filter:
Showing 39 of 39 assets
Target & Modality
Approved
TNF-alphaMonoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid ArthritisHidradenitis SuppurativaNon-Infectious Uveitis
Ulcerative Colitis, Crohn's Disease
Afatinib(Gilotrif)
Approved
EGFR/HER1, HER2, HER4Small molecule
Non-Small Cell Lung Cancer
Empagliflozin(Jardiance)
Approved
SGLT2Small molecule
Type 2 DiabetesHeart FailureChronic Kidney DiseaseAtherosclerotic Cardiovascular Disease
Approved
Insulin receptor (basal)Peptide
Type 2 DiabetesType 1 Diabetes
Approved
Muscarinic acetylcholine receptor (M3)Small molecule
Chronic Obstructive Pulmonary DiseaseAsthma
Approved
Muscarinic M3 receptor / Beta-2 adrenergic receptor (combination)Small molecule
Chronic Obstructive Pulmonary Disease
Linagliptin(Tradjenta)
Approved
DPP-4Small molecule
Type 2 Diabetes
Approved
PDE4BSmall molecule
Idiopathic Pulmonary FibrosisSystemic Sclerosis
Approved
Triple angiokinase inhibitor (VEGFR/FGFR/PDGFR)Small molecule
Idiopathic Pulmonary FibrosisSystemic Sclerosis
Approved
Beta-2 adrenergic receptorSmall molecule
Chronic Obstructive Pulmonary Disease
Approved
Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptorSmall molecule
Chronic Obstructive Pulmonary Disease
Approved
Dopamine D2 / D3 receptorsSmall molecule
Parkinson's Disease
risankizumab(Skyrizi)
Approved
IL-23 p19Monoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis
Ulcerative Colitis, Crohn's Disease
spesolimab(Spevigo)
Approved
IL-36 receptorMonoclonal antibody
PsoriasisHidradenitis Suppurativa
Approved
Muscarinic acetylcholine receptor (M3)Small molecule
Chronic Obstructive Pulmonary DiseaseAsthma

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(53 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
Zongertinib · HernexeosPhase 3Lung Cancer, Non-squamous, Non-small Cell
Est. primary completion 2026-12-10 · NCT06151574 · CT.gov ↗
What to watch
BI 1584862Phase 2Geographic Atrophy
Est. primary completion 2026-12-22 · NCT06769048 · CT.gov ↗
What to watch
VicadrostatPhase 3Kidney Disease, Chronic
Est. primary completion 2026-12-31 · NCT06531824 · CT.gov ↗
What to watch
2027 (13)
March 2027 (2)
risankizumab · SkyriziPhase 3Crohn's Disease
Est. primary completion 2027-03 · NCT06063967 · CT.gov ↗
What to watch
IfebemtinibPhase 2Ovarian Cancer Recurrent
Est. primary completion 2027-03-24 · NCT06014528 · CT.gov ↗
What to watch
April 2027 (3)
Nerandomilast (Jascayd)Phase 3Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Est. primary completion 2027-04-15 · NCT06806592 · CT.gov ↗
What to watch
Empagliflozin · JardiancePhase 3Chronic Kidney Disease
Est. primary completion 2027-04-16 · NCT07107945 · CT.gov ↗
What to watch
Nerandomilast (Jascayd)Phase 3Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Est. primary completion 2027-04-28 · NCT06238622 · CT.gov ↗
What to watch
June 2027 (1)
BI 3034701Phase 2Obesity, Overweight
Est. primary completion 2027-06-26 · NCT07662122 · CT.gov ↗
What to watch
July 2027 (1)
BI 3032950Phase 2Ulcerative Colitis
Est. primary completion 2027-07-30 · NCT06636656 · CT.gov ↗
What to watch
August 2027 (2)
risankizumab · SkyriziPhase 3Ulcerative Colitis
Est. primary completion 2027-08 · NCT06880744 · CT.gov ↗
What to watch
Zongertinib · HernexeosPhase 2Lung Cancer, Non-squamous, Non-small Cell
Est. primary completion 2027-08-12 · NCT07486817 · CT.gov ↗
What to watch
September 2027 (1)
spesolimab · SpevigoPhase 2Generalized Pustular Psoriasis
Est. primary completion 2027-09-30 · NCT03886246 · CT.gov ↗
What to watch
November 2027 (1)
spesolimab · SpevigoPhase 3Pyoderma Gangrenosum
Est. primary completion 2027-11-12 · NCT06624670 · CT.gov ↗
What to watch
December 2027 (2)
ObrixtamigPhase 2Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
Est. primary completion 2027-12-17 · NCT05882058 · CT.gov ↗
What to watch
IfebemtinibPhase 1/2Solid Tumor
Est. primary completion 2027-12-31 · NCT06166836 · CT.gov ↗
What to watch
2028 (14)
January 2028 (2)
survodutidePhase 3Type 2 Diabetes
Est. primary completion 2028-01-17 · NCT07754461 · CT.gov ↗
What to watch
ApecotrepPhase 2Proteinuric Kidney Diseases
Est. primary completion 2028-01-20 · NCT07355296 · CT.gov ↗
What to watch
February 2028 (1)
risankizumab · SkyriziPhase 3Crohn's Disease (CD)
Est. primary completion 2028-02 · NCT04524611 · CT.gov ↗
What to watch
March 2028 (1)
BI 1815368Phase 2Macular Edema
Est. primary completion 2028-03-01 · NCT06962839 · CT.gov ↗
What to watch
April 2028 (1)
risankizumab · SkyriziPhase 3Psoriasis
Est. primary completion 2028-04 · NCT04862286 · CT.gov ↗
What to watch
May 2028 (1)
VicadrostatPhase 3Heart Failure
Est. primary completion 2028-05-22 · NCT06424288 · CT.gov ↗
What to watch
July 2028 (2)
ObrixtamigPhase 3Advanced Cancer
Est. primary completion 2028-07-03 · NCT07929051 · CT.gov ↗
What to watch
survodutidePhase 3Obesity
Est. primary completion 2028-07-26 · NCT07850050 · CT.gov ↗
What to watch
September 2028 (3)
risankizumab · SkyriziPhase 3Ulcerative Colitis (UC)
Est. primary completion 2028-09 · NCT03398135 · CT.gov ↗
What to watch
IfebemtinibPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2028-09 · NCT07174908 · CT.gov ↗
What to watch
ObrixtamigPhase 3Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Est. primary completion 2028-09-09 · NCT07472517 · CT.gov ↗
What to watch
November 2028 (1)
Zongertinib · HernexeosPhase 2Solid Tumours
Est. primary completion 2028-11-30 · NCT06581432 · CT.gov ↗
What to watch
December 2028 (2)
Nerandomilast (Jascayd)Phase 3Interstitial Lung Diseases
Est. primary completion 2028-12-05 · NCT07540988 · CT.gov ↗
What to watch
ApecotrepPhase 3Focal Segmental Glomerulosclerosis
Est. primary completion 2028-12-27 · NCT07220083 · CT.gov ↗
What to watch
2029 (13)
January 2029 (1)
Zongertinib · HernexeosPhase 1/2Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma …
Est. primary completion 2029-01-08 · NCT06324357 · CT.gov ↗
What to watch
February 2029 (3)
risankizumab · SkyriziPhase 3Crohn's Disease
Est. primary completion 2029-02 · NCT03105102 · CT.gov ↗
What to watch
BI 3000202Phase 2Systemic Lupus Erythematosus
Est. primary completion 2029-02-04 · NCT07409181 · CT.gov ↗
What to watch
VicadrostatPhase 3Heart Failure
Est. primary completion 2029-02-04 · NCT06935370 · CT.gov ↗
What to watch
April 2029 (3)
risankizumab · SkyriziPhase 3Crohn's Disease
Est. primary completion 2029-04 · NCT05995353 · CT.gov ↗
What to watch
Nerandomilast (Jascayd)Phase 3Fibrosing Interstitial Lung Disease
Est. primary completion 2029-04-27 · NCT07366034 · CT.gov ↗
What to watch
survodutidePhase 3Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease
Est. primary completion 2029-04-29 · NCT07850063 · CT.gov ↗
What to watch
May 2029 (1)
Nerandomilast (Jascayd)Phase 3Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
Est. primary completion 2029-05-14 · NCT07201922 · CT.gov ↗
What to watch
June 2029 (1)
survodutidePhase 3Metabolic Dysfunction Associated Steatohepatitis
Est. primary completion 2029-06-05 · NCT06632457 · CT.gov ↗
What to watch
August 2029 (1)
risankizumab · SkyriziPhase 2Psoriatic Arthritis
Est. primary completion 2029-08 · NCT06865105 · CT.gov ↗
What to watch
November 2029 (1)
survodutidePhase 3Obesity
Est. primary completion 2029-11-06 · NCT07855900 · CT.gov ↗
What to watch
December 2029 (2)
ObrixtamigPhase 3Extrapulmonary Neuroendocrine Cancer (epNEC)
Est. primary completion 2029-12-13 · NCT07544654 · CT.gov ↗
What to watch
VicadrostatPhase 3Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Est. primary completion 2029-12-14 · NCT07064473 · CT.gov ↗
What to watch
2030 (5)
January 2030 (1)
risankizumab · SkyriziPhase 2Crohn's Disease
Est. primary completion 2030-01 · NCT06548542 · CT.gov ↗
What to watch
February 2030 (1)
Nerandomilast (Jascayd)Phase 3Systemic Sclerosis
Est. primary completion 2030-02-26 · NCT07497087 · CT.gov ↗
What to watch
March 2030 (1)
Nerandomilast (Jascayd)Phase 3Idiopathic Inflammatory Myopathies
Est. primary completion 2030-03-21 · NCT07789015 · CT.gov ↗
What to watch
April 2030 (2)
ObrixtamigPhase 1/2Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer
Est. primary completion 2030-04-17 · NCT07843940 · CT.gov ↗
What to watch
ObrixtamigPhase 1/2Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology …
Est. primary completion 2030-04-26 · NCT07707895 · CT.gov ↗
What to watch
2031 (3)
February 2031 (1)
IfebemtinibPhase 1/2Solid Tumor Cancer, PDAC
Est. primary completion 2031-02-28 · NCT07441174 · CT.gov ↗
What to watch
October 2031 (1)
risankizumab · SkyriziPhase 2Crohn's Disease, Ulcerative Colitis
Est. primary completion 2031-10 · NCT07697456 · CT.gov ↗
What to watch
December 2031 (1)
survodutidePhase 3Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Est. primary completion 2031-12-27 · NCT06632444 · CT.gov ↗
What to watch
2032 (1)
February 2032 (1)
Zongertinib · HernexeosPhase 3Non-small Cell Lung Cancer
Est. primary completion 2032-02-26 · NCT07195695 · CT.gov ↗
What to watch
2034 (1)
July 2034 (1)
risankizumab · SkyriziPhase 3Ulcerative Colitis
Est. primary completion 2034-07 · NCT07071519 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

23 October 2026ApprovalrisankizumabFDA approves SC induction regimen for Skyrizi in Crohn's disease
US, FDA · Source ↗
1 October 2026Topline resultsurvodutideSYNCHRONIZE-2 Phase III met co-primary endpoints
Boehringer Ingelheim · Source ↗
September 2026Topline resultVicadrostatEASi-KIDNEY (NCT06531824) Phase 3 stopped on DMC recommendation for lack of expected benefit
Boehringer Ingelheim · Source ↗
29 April 2026Topline resultsurvodutideSYNCHRONIZE-1 Phase III met co-primary endpoints
Boehringer Ingelheim · Source ↗
9 January 2023WithdrawalPramipexoleFDA withdraws approval of NDA 020667 (Federal Register 2022-26661)
US, FDA · Source ↗

Financial reports

No financial reports recorded.